We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day. This change lagged the S&P 500's 1.76% gain on the day. At the same time, the Dow added 1.17%, and the tech-heavy Nasdaq gained 3.03%.
Coming into today, shares of the vaccine maker had lost 42.1% in the past month. In that same time, the Medical sector lost 4.26%, while the S&P 500 lost 5.94%.
Wall Street will be looking for positivity from Novavax as it approaches its next earnings report date. The company is expected to report EPS of -$2.70, down 205.47% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $190.6 million, down 72.93% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$5 per share and revenue of $1.11 billion, which would represent changes of +40.62% and -43.79%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.42% lower. Novavax currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Gains But Lags Market: What You Should Know
Novavax (NVAX - Free Report) closed at $5.97 in the latest trading session, marking a +1.19% move from the prior day. This change lagged the S&P 500's 1.76% gain on the day. At the same time, the Dow added 1.17%, and the tech-heavy Nasdaq gained 3.03%.
Coming into today, shares of the vaccine maker had lost 42.1% in the past month. In that same time, the Medical sector lost 4.26%, while the S&P 500 lost 5.94%.
Wall Street will be looking for positivity from Novavax as it approaches its next earnings report date. The company is expected to report EPS of -$2.70, down 205.47% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $190.6 million, down 72.93% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$5 per share and revenue of $1.11 billion, which would represent changes of +40.62% and -43.79%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Novavax. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.42% lower. Novavax currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.